Home ETF List About

Portfolio Holdings Detail for ISIN IE00BL3J3G74
Stock Name / FundiShares Core S&P 500 UCITS ETF MXN Hedged (Acc)
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity Type
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCSPXx(MXN) CXE

Holdings detail for REGN

Stock NameRegeneron Pharmaceuticals Inc
TickerREGN(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS75886F1075
LEI549300RCBFWIRX3HYQ56

Show aggregate REGN holdings

News associated with REGN

Regeneron And Sanofi : CHMP Recommends EU Approval Of Dupixent For Chronic Spontaneous Urticaria
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recommending the approval of Dupixent (dupilumab) in the European Union for treating c - 2025-09-22 02:12:20
Peek Under The Hood: JEPQ Has 10% Upside
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-09-08 08:26:56
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of “Moderate Buy” by Brokerages
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) have been given an average recommendation of “Moderate Buy” by the twenty-six analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have assigned a buy rating and three […] - 2025-08-26 02:16:48
LABU, INCY, UTHR, REGN: ETF Outflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Direxion Daily S&P Biotech Bull 3x Shares (Symbol: LABU) where we have detected an approximate $67.3 million dollar outflow -- that's a 9.4% dec - 2025-08-20 12:04:03
Regeneron Pharmaceuticals (NASDAQ:REGN) versus Cadrenal Therapeutics (NASDAQ:CVKD) Head-To-Head Analysis
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) and Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings. Volatility and Risk Regeneron Pharmaceuticals has a beta […] - 2025-08-20 02:22:48
Truist Financial Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $812.00
Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target reduced by Truist Financial from $940.00 to $812.00 in a research note published on Monday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. REGN has been the topic of several other reports. The Goldman Sachs Group dropped their price target on […] - 2025-08-14 03:00:52
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Raised by Blair William & Co. IL
Blair William & Co. IL lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.2% in the 1st quarter, Holdings Channel reports. The fund owned 1,282 shares of the biopharmaceutical company’s stock after buying an additional 27 shares during the period. Blair William & Co. IL’s holdings in Regeneron Pharmaceuticals were worth […] - 2025-08-11 06:26:50
Harbour Investments Inc. Sells 32 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Harbour Investments Inc. reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 7.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 403 shares of the biopharmaceutical company’s stock after selling 32 shares during the quarter. Harbour Investments Inc.’s holdings in […] - 2025-08-07 09:40:47
We Did The Math SPYX Can Go To $58
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-07 08:58:54
409 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by Arkadios Wealth Advisors
Arkadios Wealth Advisors purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 409 shares of the biopharmaceutical company’s stock, valued at approximately $259,000. Several other institutional investors and hedge funds also […] - 2025-08-07 05:38:53
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, BMO Capital Markets Analyst Says
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price target upped by stock analysts at BMO Capital Markets from $600.00 to $640.00 in a research report issued on Monday,Benzinga reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price target indicates a potential upside of 12.30% from […] - 2025-08-06 03:12:48
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $828.86 Consensus Target Price from Brokerages
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has been given a consensus rating of “Moderate Buy” by the twenty-four ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, fifteen have assigned a buy recommendation and two […] - 2025-08-04 02:59:01
Stocks Slump on Tariffs and Weak US Job Growth
The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 19:31:54
Stocks Slump on Tariffs and Weak US Job Growth
The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:40:40
Stocks Slump on Tariffs and Weak US Job Growth
The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:35:36
Stocks Slump on Tariffs and Weak US Job Growth
The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:02:25
Nasdaq 100 Movers: MRVL, REGN
In early trading on Friday, shares of Regeneron Pharmaceuticals, topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.6%. Year to date, Regeneron Pharmaceuticals, has lost about 20.7% of its value. And the worst performing Nasdaq 100 co - 2025-08-01 11:30:09
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Choreo LLC
Choreo LLC boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 0.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,746 shares of the biopharmaceutical company’s stock after acquiring an additional 32 shares during the period. Choreo LLC’s holdings in Regeneron Pharmaceuticals […] - 2025-07-24 07:22:56
Crestwood Advisors Group LLC Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Crestwood Advisors Group LLC increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 467 shares of the biopharmaceutical company’s stock after purchasing an additional 25 shares during the quarter. Crestwood Advisors Group […] - 2025-07-24 05:47:12
Kestra Private Wealth Services LLC Has $1.31 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Kestra Private Wealth Services LLC grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 6.9% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,058 shares of the biopharmaceutical company’s stock after buying an additional 132 shares during the quarter. […] - 2025-07-23 07:50:58
Larson Financial Group LLC Has $34,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Larson Financial Group LLC lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 34.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 53 shares of the biopharmaceutical company’s stock after selling 28 shares during the quarter. Larson […] - 2025-07-23 06:30:53
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Alps Advisors Inc.
Alps Advisors Inc. raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 71.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 530 shares of the biopharmaceutical company’s stock after purchasing an additional 220 shares during the quarter. Alps Advisors Inc.’s […] - 2025-07-17 05:50:54
Stratos Wealth Partners LTD. Sells 115 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Stratos Wealth Partners LTD. trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 18.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 506 shares of the biopharmaceutical company’s stock after selling 115 shares during the period. Stratos Wealth Partners […] - 2025-07-16 04:58:54
Allworth Financial LP Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Allworth Financial LP trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 14.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 821 shares of the biopharmaceutical company’s stock after selling 137 shares during the period. Allworth Financial […] - 2025-07-15 08:20:00
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $584.00
Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target increased by UBS Group from $560.00 to $584.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock. Several other research analysts also recently commented on REGN. BMO Capital Markets reduced their price objective on Regeneron […] - 2025-07-14 03:30:48
Brown Advisory Inc. Reduces Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Brown Advisory Inc. lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,269 shares of the biopharmaceutical company’s stock after selling 247 shares during the quarter. Brown Advisory Inc.’s […] - 2025-07-13 05:54:54
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Cut by D.A. Davidson & CO.
D.A. Davidson & CO. reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.8% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 732 shares of the biopharmaceutical company’s stock after selling 21 shares during the quarter. D.A. […] - 2025-07-11 05:32:52
Brokerages Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) PT at $813.57
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has received an average recommendation of “Moderate Buy” from the twenty-five ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating, fifteen have assigned a buy rating and three have issued […] - 2025-07-10 03:07:00
DAVENPORT & Co LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
DAVENPORT & Co LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 427 shares of the biopharmaceutical company’s stock, valued at approximately $271,000. A number of other institutional […] - 2025-07-09 05:11:22
Bessemer Group Inc. Sells 3,860 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Bessemer Group Inc. decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 76.0% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,218 shares of the biopharmaceutical company’s stock after selling 3,860 shares during the period. Bessemer Group […] - 2025-07-01 05:46:52

iShares Core S&P 500 UCITS ETF MXN Hedged (Acc) REGN holdings

DateNumber of REGN Shares HeldBase Market Value of REGN SharesLocal Market Value of REGN SharesChange in REGN Shares HeldChange in REGN Base ValueCurrent Price per REGN Share HeldPrevious Price per REGN Share Held
2025-09-30 (Tuesday)241,014USD 135,514,942USD 135,514,942
2025-09-29 (Monday)240,874USD 135,070,096USD 135,070,096
2025-09-26 (Friday)240,748USD 135,757,797USD 135,757,797
2025-09-25 (Thursday)240,594REGN holding increased by 196USD 133,652,373REGN holding decreased by -5052465USD 133,652,373196USD -5,052,465 USD 555.51 USD 576.98
2025-09-24 (Wednesday)240,398USD 138,704,838USD 138,704,838
2025-09-18 (Thursday)245,264REGN holding increased by 14USD 146,842,009REGN holding increased by 3248134USD 146,842,00914USD 3,248,134 USD 598.71 USD 585.5
2025-09-17 (Wednesday)245,250REGN holding increased by 126USD 143,593,875REGN holding increased by 2632868USD 143,593,875126USD 2,632,868 USD 585.5 USD 575.06
2025-09-16 (Tuesday)245,124USD 140,961,007USD 140,961,007
2025-09-15 (Monday)245,068USD 140,323,486USD 140,323,486
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of REGN by Blackrock for IE00BL3J3G74

Show aggregate share trades of REGN

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-09-25BUY196 555.510* 651.46
2025-09-18BUY14 598.710* 651.76
2025-09-17BUY126 585.500* 652.14
2025-09-11BUY70 568.200* 652.63
2025-09-09BUY70 556.530* 653.76
2025-07-31SELL-2,214 545.460* 654.41 Profit of 1,448,853 on sale
2025-07-30BUY112 554.580* 655.00
2025-07-29BUY14 558.145* 655.58
2025-07-24BUY14 564.640* 656.13
2025-07-23BUY84 572.390* 656.63
2025-07-22BUY126 560.930* 657.22
2025-07-21BUY28 545.530* 657.90
2025-07-18SELL-141 542.520* 658.62 Profit of 92,865 on sale
2025-07-17BUY14 550.000* 659.29
2025-07-16BUY56 547.930* 659.99
2025-07-15SELL-225 547.960* 660.69 Profit of 148,655 on sale
2025-07-14BUY112 570.590* 661.26
2025-07-11SELL-28 567.740* 661.86 Profit of 18,532 on sale
2025-07-10BUY112 559.760* 662.51
2025-07-09BUY112 552.580* 663.22
2025-07-08BUY86 547.750* 663.97
2025-07-07SELL-322 538.110* 664.79 Profit of 214,063 on sale
2025-07-02SELL-406 547.740* 667.14 Profit of 270,858 on sale
2025-06-30BUY238 525.000* 668.09
2025-06-27BUY126 521.000* 669.09
2025-06-25SELL-28 520.290* 671.12 Profit of 18,791 on sale
2025-06-24BUY18 522.270* 672.15
2025-06-23BUY364 511.920* 673.26
2025-06-18SELL-84 513.580* 675.51 Profit of 56,743 on sale
2025-06-13SELL-42 529.240* 678.86 Profit of 28,512 on sale
2025-06-12BUY42 521.840* 680.00
2025-06-11BUY56 518.600* 681.17
2025-06-06SELL-70 493.220* 684.97 Profit of 47,948 on sale
2025-06-05SELL-42 483.070* 686.49 Profit of 28,833 on sale
2025-06-04SELL-56 484.930* 688.02 Profit of 38,529 on sale
2025-06-02BUY182 490.810* 691.08
2025-05-30SELL-42 490.280* 692.63 Profit of 29,091 on sale
2025-05-29BUY14 605.390* 693.31
2025-05-28SELL-14 591.850* 694.11 Profit of 9,718 on sale
2025-05-27BUY154 603.260* 694.83
2025-05-23SELL-280 588.340* 696.55 Profit of 195,035 on sale
2025-05-22SELL-308 596.850* 697.36 Profit of 214,788 on sale
2025-05-21BUY14 604.620* 698.12
2025-05-20BUY112 614.790* 698.81
2025-05-19BUY406 596.540* 699.66
2025-05-16BUY378 594.320* 700.55
2025-05-15BUY308 584.990* 701.53
2025-05-14BUY280 571.360* 702.64
2025-05-13SELL-56 574.160* 703.75 Profit of 39,410 on sale
2025-05-12BUY14 575.630* 704.86
2025-05-09BUY42 527.780* 706.42
2025-05-08SELL-406 547.670* 707.82 Profit of 287,375 on sale
2025-05-07SELL-196 560.930* 709.13 Profit of 138,990 on sale
2025-05-06BUY490 558.520* 710.49
2025-05-02BUY42 605.610* 712.43
2025-05-01SELL-70 590.000* 713.57 Profit of 49,950 on sale
2025-04-30BUY42 598.760* 714.64
2025-04-29BUY98 568.910* 716.01
2025-04-28BUY223 610.860* 717.02
2025-04-25BUY210 602.640* 718.12
2025-04-24BUY60 599.760* 719.26
2025-04-23BUY165 587.850* 720.55
2025-04-22SELL-92 585.490* 721.89 Profit of 66,414 on sale
2025-04-17BUY30 563.160* 725.10
2025-04-16BUY1,002 549.280* 726.89
2025-04-15BUY280 557.910* 728.63
2025-04-11BUY350 554.180* 732.13
2025-04-10BUY574 546.390* 734.10
2025-04-09BUY112 576.720* 735.80
2025-04-08BUY294 556.810* 737.74
2025-04-07BUY336 572.780* 739.55
2025-04-04SELL-840 573.450* 741.40 Profit of 622,776 on sale
2025-04-02BUY98 625.600* 742.70
2025-03-31SELL-378 634.230* 745.39 Profit of 281,758 on sale
2025-03-28SELL-238 637.360* 746.65 Profit of 177,702 on sale
2025-03-27SELL-70 635.830* 747.95 Profit of 52,357 on sale
2025-03-26BUY126 640.140* 749.24
2025-03-25SELL-168 634.140* 750.62 Profit of 126,105 on sale
2025-03-24BUY98 661.000* 751.72
2025-03-21BUY168 658.480* 752.87
2025-03-19BUY28 672.360* 755.03
2025-03-18SELL-252 664.960* 756.18 Profit of 190,558 on sale
2025-03-17BUY266 678.420* 757.19
2025-03-14BUY238 666.870* 758.38
2025-03-13BUY1,176 680.610* 759.42
2025-03-12BUY560 689.500* 760.36
2025-03-11BUY224 718.160* 760.94
2025-03-07BUY134 707.510* 761.92
2025-03-06SELL-126 698.440* 762.83 Profit of 96,116 on sale
2025-03-05BUY434 687.150* 763.92
2025-03-04BUY84 675.490* 765.22
2025-03-03BUY378 684.870* 766.42
2025-02-28SELL-98 698.740* 767.45 Profit of 75,210 on sale
2025-02-27BUY14 702.780* 768.44
2025-02-26SELL-28 706.940* 769.41 Profit of 21,543 on sale
2025-02-25BUY266 723.470* 770.13
2025-02-21BUY196 700.330* 772.21
2025-02-20BUY112 696.020* 773.48
2025-02-19BUY28 685.660* 774.97
2025-02-18BUY70 680.000* 776.61
2025-02-13BUY238 674.270* 782.21
2025-02-12BUY84 663.860* 784.41
2025-02-11SELL-28 665.460* 786.65 Profit of 22,026 on sale
2025-02-07SELL-112 710.000* 790.04 Profit of 88,485 on sale
2025-02-06BUY56 722.070* 791.40
2025-02-04BUY490 697.050* 794.92
2025-02-03BUY182 666.850* 797.65
2025-01-31BUY42 672.980* 800.36
2025-01-30BUY28 683.080* 802.96
2025-01-29BUY266 687.270* 805.59
2025-01-28BUY126 686.330* 808.37
2025-01-27BUY196 684.710* 811.31
2025-01-24BUY126 675.790* 814.61
2025-01-23BUY364 694.640* 817.61
2025-01-02BUY462 715.190* 820.24
2024-12-30BUY2,078 702.590* 823.34
2024-12-10BUY105 778.500* 824.55
2024-12-09BUY120 788.000* 825.56
2024-12-06BUY180 778.000* 826.92
2024-12-05BUY45 767.900* 828.66
2024-12-04BUY165 754.260* 830.91
2024-12-03BUY531 749.570* 833.46
2024-12-02BUY44 762.340* 835.75
2024-11-29SELL-384 750.220* 838.60 Profit of 322,022 on sale
2024-11-27BUY405 754.870* 844.58
2024-11-26BUY870 753.030* 851.62
2024-11-26BUY870 753.030* 851.62
2024-11-25BUY900 749.510* 855.71
2024-11-22BUY1,050 738.000* 860.61
2024-11-21BUY165 744.500* 865.66
2024-11-20BUY150 743.350* 871.22
2024-11-19BUY135 744.600* 877.25
2024-11-18BUY1,215 762.000* 883.01
2024-11-12BUY420 821.000* 886.28
2024-11-11BUY285 825.680* 889.64
2024-11-08BUY218 828.420* 893.24
2024-11-07BUY1,335 824.480* 897.54
2024-11-06BUY1,106 816.650* 902.93
2024-11-05BUY596 829.430* 914.24
2024-11-05BUY596 829.430* 914.24
2024-11-04BUY105 828.840* 921.36
2024-11-01BUY240 843.600* 928.43
2024-10-31BUY60 838.200* 937.45
2024-10-30BUY149 922.790* 939.08
2024-10-29BUY555 927.330* 940.55
2024-10-28SELL-105 928.610* 944.53 Profit of 99,175 on sale
2024-10-28SELL-105 928.610* 944.53 Profit of 99,175 on sale
2024-10-25BUY180 933.020* 950.28
2024-10-25BUY180 933.020* 950.28
2024-10-24BUY120 928.900* 957.41
2024-10-23BUY150 941.390* 965.42
2024-10-22BUY807 962.340* 968.50
2024-10-21BUY420 968.500* 0.00
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of REGN

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19208,6591,635312,81266.7%
2025-09-18236,4853,679387,51961.0%
2025-09-17229,191716370,89561.8%
2025-09-16173,632584271,02064.1%
2025-09-15204,491251334,49661.1%
2025-09-12117,50433222,76052.7%
2025-09-11125,4783,137286,51643.8%
2025-09-10195,068481339,88557.4%
2025-09-09129,168994274,52047.1%
2025-09-08250,895396527,06247.6%
2025-09-05170,149290289,56658.8%
2025-09-04188,2272,103360,61952.2%
2025-09-03185,679344438,11142.4%
2025-09-02191,954138476,28840.3%
2025-08-29133,226685236,72656.3%
2025-08-28116,5602,177256,67545.4%
2025-08-27113,719465243,83646.6%
2025-08-26210,376450400,19952.6%
2025-08-25149,13068363,37741.0%
2025-08-22211,8223,244701,77030.2%
2025-08-21257,4923,416446,43957.7%
2025-08-20327,738572559,13358.6%
2025-08-19118,4722,191324,31136.5%
2025-08-18146,282388277,90952.6%
2025-08-15209,9233,375441,75247.5%
2025-08-14157,5693,623429,32736.7%
2025-08-13111,342233362,78630.7%
2025-08-12117,647171310,77537.9%
2025-08-11129,5132,676284,75745.5%
2025-08-08128,5591,038431,84129.8%
2025-08-07166,6481,560352,87747.2%
2025-08-06176,311624397,08944.4%
2025-08-05154,257115353,74443.6%
2025-08-04200,7581,913409,89749.0%
2025-08-01349,7753,745728,72048.0%
2025-07-31222,350476549,34440.5%
2025-07-30106,8391,689231,76146.1%
2025-07-29149,359276292,66751.0%
2025-07-28103,6871,380245,28742.3%
2025-07-25103,783556259,06940.1%
2025-07-24156,9742,397291,67753.8%
2025-07-23168,7341,708355,37247.5%
2025-07-22116,324617304,88038.2%
2025-07-2198,482900250,10739.4%
2025-07-18183,1741,051391,90946.7%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.